Targeting Solid Tumors With BTK Inhibitors

Area of Science:

• Oncology
• Pharmacology

Background:

• Solid tumors present a significant challenge in cancer therapy, especially when resistant to conventional chemotherapy.
• Bruton's tyrosine kinase (BTK) inhibitors are established treatments for certain B-cell malignancies.

Purpose of the Study:

• To review the emerging evidence for the therapeutic potential of Bruton's tyrosine kinase (BTK) inhibitors in treating solid tumors.
• To explore the feasibility of repurposing FDA-approved BTK inhibitors for solid tumor indications.

Main Methods:

• Literature review of preclinical and clinical studies investigating BTK inhibitors in solid tumors.
• Analysis of emerging translational research data and clinical trial outcomes.

Main Results:

• BTK inhibitors show promise beyond their traditional use in B-cell cancers.
• Emerging evidence suggests potential efficacy in various solid tumor types.

Conclusions:

• Repurposing Bruton's tyrosine kinase (BTK) inhibitors offers a potential new avenue for treating chemotherapy-resistant solid tumors.
• Further lead optimization and translational research are crucial for developing effective BTK inhibitor combination regimens for advanced solid tumors.